Moving CRISPR-based therapies from discovery to dosing patients in clinical trials and ultimately to approval involves navigating a challenging terrain of highs and lows. In this interview, physician-scientist Kiran Musunuru and genome editor Fyodor Urnov reflect on the past 20 years of their nonclinical and clinical programs in the field, the current landscape of innovation, and what they see on the horizon.
Get full access to this article
View all access options for this article.
References
1.
KanMJ, DoudnaJA. Treatment of genetic diseases with CRISPR genome editing. JAMA, 2022; 328(10):980–981; doi: 10.1001/jama.2022.13468
2.
SahaK, SontheimerEJ, BrooksPJ, et al.; SCGE Consortium. The NIH somatic cell genome editing program. Nature, 2021; 592(7853):195–204; doi: 10.1038/s41586-021-03191-1
3.
UrnovFD. Give Cas a chance: An actionable path to a platform for CRISPR cures. CRISPR J, 2024; 7(5):212–219; doi: 10.1089/crispr.2024.0082
4.
MusunuruK, ChadwickAC, MizoguchiT, et al.In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature, 2021; 593(7859):429–434; doi: 10.1038/s41586-021-03534-y
5.
UrnovFD, MillerJC, LeeYL, et al.Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature, 2005; 435(7042):646–651; doi: 10.1038/nature03556
6.
BakerDJ, LevineBL, JuneCH. Assessing the oncogenic risk: The long-term safety of autologous chimeric antigen receptor T cells. Lancet, 2025; 405(10480):751–754; doi: 10.1016/s0140-6736(25)00039-x
7.
BhatS, DamodarS, ThirumalairajR, et al.Varnimcabtagene Autoleucel (IMN-003A): Pharmacokinetic profile with predominant naïve and central memory phenotype demonstrates sustained in vivo persistence and durable responses in a first-in-India industry phase-2 study (IMAGINE). Blood, 2023; 142(Suppl 1):6876–6876.
8.
LekA, WongB, KeelerAM, et al.Unexpected death of a duchenne muscular dystrophy patient in an N-of-1 trial of rAAV9-delivered CRISPR-transactivator. medRxiv, 2023; doi: 10.1101/2023.05.16.23289881
